{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-025156","form_type":"8-K","ticker":"ACUT","cik":"0001850767","company_name":"Accustem Sciences Inc.","filed_at":"2025-11-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.809459+00:00","generated_at":"2026-05-16T16:35:41.053566+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"AccuStem submits Medicare coverage application for MSC lung cancer test; enters Novitas review","bullets":["Submitted local coverage determination to Novitas Solutions for MSC test reimbursement.","Novitas confirmed application complete and valid; now in review queue for JL region (DC, DE, MD, NJ, PA).","MSC test analyzes 24 circulating microRNAs in plasma to classify lung nodule risk.","If approved, could reduce unnecessary biopsies for benign nodules and prioritize high-risk patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-025156","json":"https://secwatch.observer/filing/0001493152-25-025156.json","markdown":"https://secwatch.observer/filing/0001493152-25-025156.md","text":"https://secwatch.observer/filing/0001493152-25-025156.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1850767/000149315225025156/0001493152-25-025156-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1850767/000149315225025156/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T16:35:41.053566+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}